Predictors of Breakthrough SARS-CoV-2 Infection after Vaccination

Author:

Walmsley Sharon12ORCID,Nabipoor Majid3,Lovblom Leif Erik3,Ravindran Rizani1,Colwill Karen4ORCID,McGeer Alison5,Dayam Roya Monica4,Manase Dorin6,Gingras Anne-Claude47,

Affiliation:

1. Division of Infectious Diseases, Department of Medicine, University Health Network, Toronto, ON M5G1L7, Canada

2. Department of Medicine, University of Toronto, Toronto, ON M5S1A1, Canada

3. Biostatistics Department, University Health Network, Toronto, ON M5G1L7, Canada

4. Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health, Toronto, ON M5G1X5, Canada

5. Mount Sinai Hospital, Sinai Health, Toronto, ON M5G1X5, Canada

6. DATA Team, University Health Network, Toronto, ON M5G1L7, Canada

7. Department of Molecular Genetics, University of Toronto, Toronto, ON M5S1A1, Canada

Abstract

The initial two-dose vaccine series and subsequent booster vaccine doses have been effective in modulating SARS-CoV-2 disease severity and death but do not completely prevent infection. The correlates of infection despite vaccination continue to be under investigation. In this prospective decentralized study (n = 1286) comparing antibody responses in an older- (≥70 years) to a younger-aged cohort (aged 30–50 years), we explored the correlates of breakthrough infection in 983 eligible subjects. Participants self-reported data on initial vaccine series, subsequent booster doses and COVID-19 infections in an online portal and provided self-collected dried blood spots for antibody testing by ELISA. Multivariable survival analysis explored the correlates of breakthrough infection. An association between higher antibody levels and protection from breakthrough infection observed during the Delta and Omicron BA.1/2 waves of infection no longer existed during the Omicron BA.4/5 wave. The older-aged cohort was less likely to have a breakthrough infection at all time-points. Receipt of an original/Omicron vaccine and the presence of hybrid immunity were associated with protection of infection during the later Omicron BA.4/5 and XBB waves. We were unable to determine a threshold antibody to define protection from infection or to guide vaccine booster schedules.

Funder

Public Health Agency of Canada

Canadian Institutes of Health Research

University Health Network Foundation

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3